These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

367 related items for PubMed ID: 31023843

  • 1. The effect of gefapixant, a P2X3 antagonist, on cough reflex sensitivity: a randomised placebo-controlled study.
    Morice AH, Kitt MM, Ford AP, Tershakovec AM, Wu WC, Brindle K, Thompson R, Thackray-Nocera S, Wright C.
    Eur Respir J; 2019 Jul; 54(1):. PubMed ID: 31023843
    [Abstract] [Full Text] [Related]

  • 2. Gefapixant, a P2X3 receptor antagonist, for the treatment of refractory or unexplained chronic cough: a randomised, double-blind, controlled, parallel-group, phase 2b trial.
    Smith JA, Kitt MM, Morice AH, Birring SS, McGarvey LP, Sher MR, Li YP, Wu WC, Xu ZJ, Muccino DR, Ford AP, Protocol 012 Investigators.
    Lancet Respir Med; 2020 Aug; 8(8):775-785. PubMed ID: 32109425
    [Abstract] [Full Text] [Related]

  • 3. P2X3 receptor antagonist (AF-219) in refractory chronic cough: a randomised, double-blind, placebo-controlled phase 2 study.
    Abdulqawi R, Dockry R, Holt K, Layton G, McCarthy BG, Ford AP, Smith JA.
    Lancet; 2015 Mar 28; 385(9974):1198-205. PubMed ID: 25467586
    [Abstract] [Full Text] [Related]

  • 4. Efficacy and safety of gefapixant, a P2X3 receptor antagonist, in refractory chronic cough and unexplained chronic cough (COUGH-1 and COUGH-2): results from two double-blind, randomised, parallel-group, placebo-controlled, phase 3 trials.
    McGarvey LP, Birring SS, Morice AH, Dicpinigaitis PV, Pavord ID, Schelfhout J, Nguyen AM, Li Q, Tzontcheva A, Iskold B, Green SA, Rosa C, Muccino DR, Smith JA, COUGH-1 and COUGH-2 Investigators.
    Lancet; 2022 Mar 05; 399(10328):909-923. PubMed ID: 35248186
    [Abstract] [Full Text] [Related]

  • 5. BLU-5937: A selective P2X3 antagonist with potent anti-tussive effect and no taste alteration.
    Garceau D, Chauret N.
    Pulm Pharmacol Ther; 2019 Jun 05; 56():56-62. PubMed ID: 30902655
    [Abstract] [Full Text] [Related]

  • 6. Update on the clinical development of gefapixant, a P2X3 receptor antagonist for the treatment of refractory chronic cough.
    Muccino D, Green S.
    Pulm Pharmacol Ther; 2019 Jun 05; 56():75-78. PubMed ID: 30880151
    [Abstract] [Full Text] [Related]

  • 7.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 8.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 9.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 10.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 11.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 12. Gefapixant: First Approval.
    Markham A.
    Drugs; 2022 Apr 05; 82(6):691-695. PubMed ID: 35347635
    [Abstract] [Full Text] [Related]

  • 13.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 14.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 15. Eliapixant (BAY 1817080), a P2X3 receptor antagonist, in refractory chronic cough: a randomised, placebo-controlled, crossover phase 2a study.
    Morice A, Smith JA, McGarvey L, Birring SS, Parker SM, Turner A, Hummel T, Gashaw I, Fels L, Klein S, Francke K, Friedrich C.
    Eur Respir J; 2021 Nov 05; 58(5):. PubMed ID: 33986030
    [Abstract] [Full Text] [Related]

  • 16. Single- and Multiple-Dose Pharmacokinetics of Gefapixant (MK-7264), a P2X3 Receptor Antagonist, in Healthy Adults.
    Nussbaum JC, Hussain A, Butera P, Ford AP, Kitt MM, O'Neill EA, Smith S, Vargas G, O'Reilly T, Wynne C, Stoch SA, Iwamoto M.
    J Clin Pharmacol; 2024 Aug 05; 64(8):1023-1029. PubMed ID: 38651193
    [Abstract] [Full Text] [Related]

  • 17. Pharmacodynamic modeling of cough responses to capsaicin inhalation calls into question the utility of the C5 end point.
    Hilton EC, Baverel PG, Woodcock A, Van Der Graaf PH, Smith JA.
    J Allergy Clin Immunol; 2013 Oct 05; 132(4):847-55.e1-5. PubMed ID: 23777849
    [Abstract] [Full Text] [Related]

  • 18. Safety, Pharmacodynamics, and Pharmacokinetics of P2X3 Receptor Antagonist Eliapixant (BAY 1817080) in Healthy Subjects: Double-Blind Randomized Study.
    Friedrich C, Francke K, Gashaw I, Scheerans C, Klein S, Fels L, Smith JA, Hummel T, Morice A.
    Clin Pharmacokinet; 2022 Aug 05; 61(8):1143-1156. PubMed ID: 35624408
    [Abstract] [Full Text] [Related]

  • 19.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 20.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 19.